If You'd Invested $1,000 in Moderna Stock 5 Years Ago, Here's How Much You'd Have Today
Five years ago, pharmaceutical company (NASDAQ: MRNA) was mostly unknown. It was developing vaccines that induce human immune cells to more effectively fight disease. But the science of DNA-based drugs was on the experimental fringe of the biopharma landscape. Not too many investors were looking to make such a bet.
Then the COVID-19 pandemic materialized. As it turns out, the coronavirus was the ideal target for Moderna's biotechnology. In December 2020, the U.S. Food and Drug Administration approved its COVID vaccine for emergency use. Other nations' regulatory bodies followed suit.
The rest, as they say, is history.
Source Fool.com
Moderna Inc. Stock
€153.60
1.360%
With 16 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
However, we have a potential of -2.34% for Moderna Inc. as the target price of 150 € is below the current price of 153.6 €.
